Dyadic International 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Total revenue for the 3rd quarter of 2026 was approximately $449,000, down 61% from approximately $1,165,000 in the 3rd quarter of 2025, primarily because of lower grant revenue and research and development revenue.
- Revenue for the first 9 months of 2026 was $2.5 million, essentially flat compared to the same period in 2025.
- Internal research and development expenses decreased 25% year over year to approximately $430,000 in the quarter; G&A expenses decreased 2% to approximately $1.45 million.
- Net loss for the quarter was approximately $1.4 million, or $0.04 per share, compared to approximately $2 million, or $0.06 per share, in the 3rd quarter of 2025.
- Dyadic ended the quarter with approximately $6 million in cash, cash equivalents, restricted cash, and investment-grade securities including accrued interest, compared to approximately $8.6 million at year-end.
- Dyadic recorded its first direct commercial protein product sales, primarily involving recombinant transferrin and DNAse I; management said the sales were not yet financially material.
- IBT Bioservices launched an initial portfolio of 6 Dyadic-produced research-use-only recombinant protein products through its distribution network.
- Proliant Health and Biologicals continued commercial activities around AlbuFree DX, recombinant human serum albumin produced using Dyadic's C1 platform.
- Enzymes commercialized its second chymosin product using Dyadic's Dapivus platform, with its first commercial sale of Dapivus-produced camel chymosin occurring in October.
- Dyadic expanded its collaboration with BrigBio and Strive Nutrition to develop and scale Dapivus-produced bovine alpha-lactalbumin for Strive's nutritional products.
- Firmbox Bio launched Entrysyme, an AdaptiBus-produced enzyme product targeting biomass processing applications.
- Under an approximately $3.1 million Gates-funded program, C1 achieved productivity yields of approximately 12.1 grams per liter for RSV monoclonal antibody RSMA-1 and 13.2 grams per liter for malaria monoclonal antibody MAMA-1 in 7-day fermentations; both antibodies demonstrated approximately 90% human N-like glycan structures.
- Following quarter end in October 2026, the Gates Medical Research Institute initiated preclinical animal studies comparing the pharmacokinetics of C1-produced RSV and malaria antibodies with their respective GMP CHO-produced counterparts.
- Through a $4.5 million CEPI-funded program with Fondazione Biotecnopoli di Siena, Dyadic developed a C1 workflow that reduced the antigen development timeline from several months to approximately 15 days and produced 2 Scripps Research-designed Bundibugyo Ebola antigens in approximately 15 days.
- Dyadic reported producing a Bundibugyo Ebola monoclonal antibody from plasmid to a clonal production strain and protein A purified antibody in approximately 7 weeks.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good evening and welcome to Dyadic International's Q3 2026 conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief question and answer session. As a reminder, this conference call is being recorded today, November 12, 2026. I would now like to turn the call over to Ms. Ping Rawson, Dyadic's Chief Financial Officer. Please go ahead. Thank you.
Good evening and welcome everyone to Dyadic's third quarter 2026 conference call. I hope you have had the opportunity to review Dyadic's press release announcing financial results for the quarter ended September 30, 2026. You may access our release under the Investors section of the company's website at dyadic.com. Before we begin, I want to let you know that due to a Microsoft Outlook issue that has impacted many organizations, including Dyadic, we have not yet filed our quarterly report on Form 10-Q for the quarter ended September 30, 2026. We expect to file the Form 10-Q as soon as the system is back online and within the SEC filing deadline. The financial results we will discuss today are those in our press release, and they will be reflected in the Form 10-Q.
On today's call, our President and Chief Operating Officer, Joe Hazelton, will review our Q3 2026 business and corporate highlights and provide a commentary on the strategic direction of the company. Our CEO, Mark Emalfarb, will provide an update on our biopharmaceutical programs, and I will follow with a review of our financial results in more detail, after which we will hold a brief question and answer session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements, which involve risks and uncertainties and other factors that could cause Dyadic's actual results, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. Dyadic expressly disclaims any duty to provide updates to its forward-looking statements, whether because of new information, future events, or otherwise.
Participants are directed to the risk factors set forth in Dyadic's reports filed with the SEC. It is now my pleasure to pass the call to our President and COO, Joe Hazelton.
Joe? Thanks, Ping, and thank you everyone for joining us today.
Over the past several quarters, we've discussed Dyadic's transition from primarily developing protein production technologies toward building commercial businesses around our C1 and Dapibus platforms. During the third quarter, we continued making progress in that transition through initial direct product sales, broader distribution, additional partner commercialized products, and advancing discussions with companies interested in our technologies and protein production portfolio. While these developments are encouraging, I want to put them in perspective. Our direct commercial sales remain modest, and customer qualification and adoption are taking longer than we originally anticipated. While we still have work ahead of us to establish meaningful and recurring product revenue, we are beginning to demonstrate that our protein production platforms can support commercial products through multiple business models, including direct sales, distribution, licensing, and partner-led commercialization.
Importantly, we believe our decades of commercial experience put us in a stronger position to pursue larger strategic opportunities. Now, let's walk through some of the developments during the quarter and explain how they connect to our broader strategy. Starting with life sciences, during the third quarter, Dyadic recorded its first direct commercial protein product sales, primarily involving recombinant transferrin and DNase I. While these sales are not yet financially material, they further demonstrate that Dyadic can develop and commercialize recombinant enzymes and proteins, validating the potential of our proprietary fungal expression systems and complementing the products already being commercialized through our partners. Our immediate priority is to convert initial purchases and ongoing customer evaluations into repeat business. We continue to see increased sampling requests and customer evaluations, particularly for human and bovine transferrin across research, cell culture, and cultured meat applications.
Transferrin remains an important commercial focus because of its role in cell culture media and the potential demand for consistent animal-free alternatives. As we've discussed previously, improvements in production yields and manufacturing economics are important to making these products competitive, but the qualification process takes time for higher value segments like cell culture media. Customers need to establish that a replacement protein performs consistently in their specific applications, meets their quality requirements, and can be supplied reliably at acceptable economics. We're supporting those evaluations and working to expand our customer base, but we recognize that the conversion from sampling to recurring purchases has been slower than anticipated. Alongside our direct sales efforts, we continue to expand our commercial reach through third-party distribution. IBT Bioservices has now launched an initial portfolio of six Dyadic-produced research-use-only recombinant protein products through its distribution network.
This relationship provides access to an established customer base without requiring Dyadic to build substantial direct sales organization. We're also evaluating additional products for distribution and pursuing opportunities with other distributors and commercial partners. Our objective remains to build a capital-efficient commercial model that leverages established channels and partners. Another important part of our strategy is working with established companies that can take products developed using our platforms into their respective markets. Proliant Health and Biologicals continues to expand its commercial activities around AlbuFree DX, its recombinant human serum albumin produced using Dyadic's C1 platform. Proliant has been presenting performance and analytical data supporting applications in diagnostic assays and protein stabilization, and has outlined plans to introduce additional products targeting cell culture media and cell and gene therapy applications.
These activities provide an opportunity to expand the number of commercial applications for animal-free albumin, with potential future revenue participation for Dyadic under our commercial arrangements. In food and nutrition, our partner Inzymes has now commercialized its second chymosin product using our Dapibus platform. In November, Inzymes informed us that its first commercial sale of Dapibus-produced camel chymosin occurred in October. As a result, we expect to receive a $225,000 contractual payment and recognize the associated revenue during the fourth quarter. This follows the earlier commercialization of bovine chymosin and further demonstrates the ability to develop and commercialize different products using the Dapibus production system. What is particularly relevant about Proliant Inzymes is that these are established commercial organizations bringing products produced with Dyadic's technologies to market.
Although the revenue contribution to Dyadic remains at an early stage, these relationships provide evidence of commercial applicability that can be valuable when evaluating broader licensing, supply, and strategic partnership opportunities. Also in our food and nutrition business, alpha-lactalbumin remains one of our highest priority development and commercial opportunities. We continue to advance our collaboration with BRIG BIO to develop and scale Dapibus-produced bovine alpha-lactalbumin, an animal-free dairy protein with potential applications in nutritional products. Recently, we announced an expanded strategic collaboration with BRIG BIO and Strive Nutrition, bringing together complementary capabilities across the entire value chain, from Dyadic's Dapibus protein production platform and strain optimization expertise to manufacturing scale-up, commercialization, and integration into finished consumer products. Importantly, this collaboration aligns protein development and manufacturing capabilities with Strive Nutrition, the intended end customer, which plans to integrate our precision-fermented animal-free alpha-lactalbumin into its next-generation nutritional products.
We believe this integrated approach provides a more direct pathway toward commercial-scale production, market adoption, and potential recurring revenue opportunities. Our technical focus remains on improving production yields, protein quality, and manufacturing economics to support competitive commercial-scale production. While we're encouraged by the progress, further optimization, application testing, regulatory work, and scale-up remain necessary before commercial production can be established. We're also continuing discussions with additional global companies regarding potential licensing, development, and commercial arrangements involving alpha-lactalbumin and other animal-free proteins in our portfolio. These discussions are particularly relevant because the larger food and nutrition markets require manufacturing capacity, capital investment, regulatory expertise, and established commercial distribution. Our strategy is to work with companies that already possess these capabilities rather than attempting to build the entire commercial infrastructure ourselves.
Beyond bovine alpha-lactalbumin, we have developed production strains for human alpha-lactalbumin and human lactoferrin and are actively exploring licensing and strategic partnership opportunities for these products. We have also initiated development of recombinant bovine lactoferrin, further expanding our portfolio of animal-free nutritional proteins. In addition, we continue to advance other dairy proteins and enzymes through internal development programs and external collaborations, broadening the range of potential applications and commercial opportunities for our platforms. We believe this expanding portfolio, combined with a growing interest from potential commercial partners, positions Dyadic to pursue broader strategic relationships across the food nutrition market. In our bioindustrial segment, we continue to expand applications for our Dapibus platform across industrial enzymes and biomass processing. Our partner Fermbox Bio has launched EN3ZYME, a Dapibus-produced enzyme product targeting biomass processing applications.
We're also developing additional enzymes for use across biofuels, food and feed, and textile and paper processing markets. We are seeing increased interest in EN3ZYME and other industrial enzyme solutions, particularly in the biofuels and ethanol markets, where volatility in energy markets is contributing to renewed interest in alternative fuels and improved production economics. This has translated into a significant increase in sampling activity and discussions with potential customers and strategic partners. We believe our ability to develop customized enzyme solutions, combined with the manufacturing efficiency and scalability of Dapibus, creates opportunities to address the evolving needs of these industries. As with our other commercial businesses, our focus is on working with partners that bring established manufacturing capabilities, industry expertise, and customer relationships to accelerate commercializations while limiting the capital Dyadic would otherwise need to invest independently.
When we look across our businesses, we believe the progress we have made in commercializing products, both directly and through our partners, is strengthening the strategic value of our C1 and Dapibus platforms. We now have several examples of our technology supporting commercial products and generating revenue through different business models. Proliant has commercialized recombinant human albumin using C1. Inzymes has commercialized two chymosin products using Dapibus, and EN3ZYME has entered the industrial market. These relationships demonstrate our ability to develop products that can be commercialized through established partners. More recently, our collaboration with BRIG BIO and Strive Nutrition brings together the key elements of the commercial value chain for Dapibus-produced alpha-lactalbumin, from strain development and manufacturing scale-up through to Strive, the intended end customer. This vertically integrated partnership provides a defined pathway toward potential commercial supply, subject to successful development, scale-up, and product qualification.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
